Amgen

Open: 221.21 Close: 225.01 Change: 3.8

Don't invest before reading what an AI found about Amgen Company Inc.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, Amgens, Inc, AMGN, Top, sell, and the most common words in the summary are: amgen, drug, company, amgens, inc, article, patent, . One of the sentences in the summary was: Am Gen and Horizon Therapeutics have filed counterclaims against the Federal Trade Commission.. Other …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Insiders at Amgen sold US$1.9m in stock, alluding to potential weakness. Amgen short percent of float has fallen 4.93% since its last report. Am Gen and Horizon Therapeutics have filed counterclaims against the Federal Trade Commission.

Today's News

Amgen Inc. (AMGN) Latest Stock News | Seeking Alpha. Find & Compare Top Stocks Top ETFs Top. Insiders at Amgen sold US$1.9m in stock, alluding to potential weakness. The biggest insider sale was by the Lead Independent Director, Robert Eckert, for US $1.6m. Amgens short percent of float has fallen 4.93% since its last report. Amgen has less short interest than most of its peers. Amgen is one of the worlds leading independent biotech companies, with a market capitalisation of approximately $130bn. Robert Bradway: Amgens ambition is to halve the number of cardiovascular events by 2030. amgen, horizon lodge constitutional attack on ftc - law360.com. Amgen, Horizon Lodge Constitutional Attack On FTC. Am Gen and Horizon Therapeutics have filed counterclaims against the Federal Trade Commission. U.S. Supreme Court issued its decision in Amgen v. Sanofi ruling. The Court held that the 26 antibody examples and detailed instructions for generating additional antibodies within the genus. Amgen has been pursuing novel treatment approaches for more than 40 years. FDA has granted full approval for Amgens treatment for adult and pediatric patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. Amgen Oncology: Are you testing your patients with advanced non-small cell lung cancer for all actionable biomarkers? Amgen Inc (Symbol: AMGN) : Select Medical Holdings Corp : Laboratory Corporation of America Holdings (symbol: LH) Amgen shares open for trading on 5/17/23. Amgen went public on June 17, 1983, selling two million common shares and raising nearly $40 million. In October, Amgen named George Rathmann its first president and chief executive officer. Amgen joined the Dow Jones Industrial Average on August 24, 2020. Amgen announced it would be acquiring a 20.5% stake in the Beijing -based BeiGene for $2.7 billion. Amgen: This Beaten Down Blue Chip Is Priced To Own Amgen Inc. (AMGN) stock price, quote & news - stock analysis. Company Profile Financial Performance In 2022, Amgens revenue was $26 billion. Amgen will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. on May 26, 2023. Analysts have conflicting sentiments on these healthcare companies: alnylam pharma (alny) and amgen (amgn) See todays best-performing stocks on TipRanks.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, Amgens, Inc, AMGN, Top, sell, and the most common words in the summary are: amgen, drug, company, amgens, inc, article, patent, . One of the sentences in the summary was: Am Gen and Horizon Therapeutics have filed counterclaims against the Federal Trade Commission.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #drug #company #amgens #inc #article #patent.